Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, already real and recurring, and early stage. In the transcript, Deverl mentions: "we are seeing net new customer sales growth and increased drop sizes at our long-term customer locations." That's about drop sizes increasing, but is that about new engagements? It says "increased drop sizes at our long-term customer locations" - that's existing customers, not new engagements. Also "more routes running over $1 million of annualized sales than we've had in many years" - that's about route performance, not necessarily new deals. Later: "we are seeing others get back, which is presenting us with opportunities to expand our current offerings in these markets." That's about opportunities, not actual larger deals. Scott mentions: "we saw increased drop sizes at our long-term customer sites and we continue to see new customer sales growth year-to-date." Again, drop sizes at existing sites. No explicit statement that new customers or new contracts are larger than before. The company talks about volume recovery, price increases, but not about the unit size of engagements escalating. They mention "more routes running over $1 million" but that's about route sales, not about new contracts being larger. Also, they talk about "net new customer sales growth" but not that each new customer is bigger. Thus, no clear expression of escalating unit size. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.